Gene Delivery
Inomagen is developing a proprietary gene delivery system utilizing reversible electroporation
Delivery of genetic material to the cardiac atrium (the source of AF) is notoriously difficult with existing methods.
Inomagen has solved this with a novel transvenous method of facilitating endocardial gene delivery using Reversible Electroporation.
Our catheter applies a low-voltage electric field to cells, increasing the permeability of the cell membrane, allowing DNA to be introduced.
This method allows for genetic material, packaged in Naked Plasmid DNA, to only be delivered directly to a specific site with no off-target effects!
Inomagen’s extensive SBIR Phase I large animal work has developed valuable gene therapy parameters.
Inomagen’s Gene Delivery System will be a Procedure that is Familiar to Physicians and Staff
Inomagen's Large Area Multi-polar Electroporation (LAMPE) procedure mirrors the steps of existing catheter ablation—leveraging existing provider skills and facilitating easy adoption while allowing for targeted gene delivery instead of destructive ablation
Inomagen's gene delivery system has the potential to become a platform technology for endovascular gene delivery
Gene therapy in the ventricle is a rapidly growing area, with many companies developing AAV-based gene therapies for heart failure/cardiomyopathy.
AAV has been the main vector for delivering these gene therapies into the heart, however recent major setbacks in the field have exposed AAV’s shortcomings including inflammation-related toxicity and even death in recent trials
Gene therapy companies are seeking safe and more effective gene delivery solutions to bring their life-saving therapies to patients.